Last reviewed · How we verify
Pegylated rhG-CSF regimen
Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.
Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts. Used for Chemotherapy-induced neutropenia (CIN), Severe congenital neutropenia, Idiopathic or cyclic neutropenia.
At a glance
| Generic name | Pegylated rhG-CSF regimen |
|---|---|
| Sponsor | Shandong Provincial Hospital |
| Drug class | G-CSF receptor agonist |
| Target | G-CSF receptor (CSF3R) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their maturation into functional neutrophils. Pegylation extends the drug's half-life by reducing renal clearance and increasing circulation time, allowing for less frequent dosing compared to non-pegylated G-CSF. This results in sustained elevation of neutrophil counts, reducing infection risk in patients with chemotherapy-induced neutropenia or other causes of low neutrophil counts.
Approved indications
- Chemotherapy-induced neutropenia (CIN)
- Severe congenital neutropenia
- Idiopathic or cyclic neutropenia
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
- Elevated uric acid
Key clinical trials
- Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (PHASE4)
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma (PHASE3)
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (PHASE1, PHASE2)
- CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients (PHASE2)
- Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (PHASE2)
- Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients (PHASE3)
- Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies (NA)
- Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated rhG-CSF regimen CI brief — competitive landscape report
- Pegylated rhG-CSF regimen updates RSS · CI watch RSS
- Shandong Provincial Hospital portfolio CI